Clinical Report: Evaluating the Diagnostic Value of Calcium-Chloride Ratio

Overview

This study evaluates the diagnostic performance of the calcium-chloride/phosphorus ratio combined with alkaline phosphatase in differentiating subtypes of primary hyperparathyroidism. The findings indicate high sensitivity and specificity for diagnosing hypercalcemic and normocalcemic primary hyperparathyroidism.

Background

Primary hyperparathyroidism (PHPT) is a common endocrine disorder that can lead to significant morbidity if undiagnosed. Differentiating between its subtypes, hypercalcemic PHPT (HPHPT) and normocalcemic PHPT (NPHPT), is crucial for appropriate management. Current diagnostic methods may not adequately distinguish between these subtypes, highlighting the need for reliable biomarkers.

Data Highlights

Key Findings

• HPHPT patients had higher ALP and ([Ca]×[Cl])/P levels compared to NPHPT and controls.
• The AUC for ([Ca]×[Cl])/P in diagnosing PHPT was 0.960.
• Combining ([Ca]×[Cl])/P and ALP yielded an AUC of 0.983, with sensitivity of 94.8% and specificity of 98.5%.
• The AUC for differentiating HPHPT from NPHPT was 0.881.
• Adenoma prevalence was significantly higher in the HPHPT group (83.12%) compared to the NPHPT group (60.34%).

Clinical Implications

The combination of the calcium-chloride/phosphorus ratio and alkaline phosphatase can enhance the diagnostic accuracy for primary hyperparathyroidism and its subtypes. This approach may be particularly useful in settings with limited access to advanced diagnostic tools.

Conclusion

The study supports the use of combined biochemical markers for improved diagnosis and differentiation of primary hyperparathyroidism subtypes, which may lead to better patient management.

Related Resources & Content

1. BMC Endocrine Disorders, 2026 -- Utility of albumin-adjusted calcium and calcium‒phosphorus difference in screening for primary hyperparathyroidism
2. The Journal of Clinical Endocrinology & Metabolism, 2025 -- Managing Patients with Normocalcemic Primary Hyperparathyroidism
3. Limited utility of [99mTc]-sestamibi scintigraphy in patients with primary hyperparathyroidism and negative ultrasound results, 2022
4. The Journal of Clinical Endocrinology & Metabolism — Assessment of the Thiazide Challenge Test for Distinguishing Primary Hyperparathyroidism from Hypercalciuria-Induced Secondary Hyperparathyroidism
5. Primary hyperparathyroidism - Symptoms, diagnosis and treatment | BMJ Best Practice US
6. Approach to the Patient: Normocalcemic Primary Hyperparathyroidism - PubMed
7. Hypercalcaemia and primary hyperparathyroidism - ScienceDirect
8. Primary Hyperparathyroidism - StatPearls - NCBI Bookshelf
9. Utility of albumin-adjusted calcium and calcium‒phosphorus difference in screening for primary hyperparathyroidism - PMC
10. The Ca∗Cl/P Ratio: A Novel and More Appropriate Screening Tool for Normocalcaemic or Overt Primary Hyperparathyroidism - ScienceDirect
11. Bone metabolism in primary hyperparathyroidism - PMC
12. Bone Disease in Primary Hyperparathyroidism—Changes Occurring in Bone Metabolism and New Potential Treatment Strategies - PMC
13. Bone Mineral Density Outcomes After Parathyroidectomy in Primary Hyperparathyroidism and Osteopenia: A Meta-Analysis and Meta-Regression - ScienceDirect
14. Effect of parathyroidectomy versus conservative management on bone mineral density in patients with primary hyperparathyroidism - ScienceDirect
15. Effect of parathyroidectomy on stone recurrence in primary hyperparathyroidism: A systematic review - PMC